Atlas acs 2 timi 51 was arandomized, double blinded, placebo controlled trial that enrolled 15,526 subjects with an acs to either placebo or rivaroxaban. Methods study population the study included patients. Mega, eugene braunwald, sabina murphy, alexei plotnikov, nancy cookbruns, philip aylward, vijay chopra, runlin gao, jose nicolau and c. Rivaroxaban in patients with a recent acute coronary syndrome article pdf available in new england journal of medicine 3661. Atlas acs2timi51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction51 is the largest study to date to test a novel xa inhibitor, rivaroxaban, in patients with an acute coronary syndrome acs. Anticoagulation and antiplatelet therapy in acute coronary. On the basis of the graded increase in bleeding across doses of rivaroxaban in both strata 1 and 2 in conjunction with the efficacy noted at lower doses of the factor xa inhibitor, 25 mg and 5 mg of rivaroxaban administered twice daily have been selected for further assessment in a large, phase iii clinical trial atlas acs 2timi 51. Atlas acs2, timi 51 2012 randomized 15,342 patients with recent acs to either twicedaily doses of either 2. The company said the drug was associated with a statistically significant reduction in the primary composite end. Whether that risk can be safely reduced by adding an anticoagulant to post acs therapy was addressed in the atlas acs 2 timi 51 trial, which found that rivaroxaban was associated with a reduction in. Efficacy and safety data are consistent with results of the.
Since factor xa plays a central role in thrombosis, the. Gibson cm1, chakrabarti ak, mega j, bode c, bassand jp, verheugt fw, bhatt dl, goto s, cohen m, mohanavelu s, burton p, stone g, braunwald e. The effect of rivaroxaban on myocardial infarction in the. The atlas acs 2 timi 51 trial and the burden of missing data antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome acs 2 thrombolysis in myocardial infarction 51 mori j. The trial was sponsored by janssen scientific affairs and bayer. Antithrombotic therapy in patients with recent acs.
Rivaroxaban for preventing adverse outcomes after acute. Reduction of stent thrombosis in patients with acute. Rivaroxaban in patients stabilized after a stsegment elevation myocardial infarction. Rivaroxaban is a selective direct factor xa inhibitor that is used to prevent and treat venous thromboembolism and to prevent stroke or systemic embolism in atrial fibrillation. Results of the highly anticipated atlas acs 2 timi 51 demonstrate that acs patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the. Michael gibson, ms, md on behalf of the atlas acs 2. An efficacy and safety study for rivaroxaban in patients with. On the basis of the graded increase in bleeding across doses of rivaroxaban in both strata 1 and 2 in conjunction with the efficacy noted at lower doses of the factor xa inhibitor, 2 5 mg and 5 mg of rivaroxaban administered twice daily have been selected for further assessment in a large, phase iii clinical trial atlas acs 2 timi 51. Standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2timi 51 are listed in the supplementary appendix, available at.
Antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction 51. Atlas acs 2 timi 51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 is the largest study to date to test a novel xa inhibitor, rivaroxaban, in patients with an acute coronary syndrome acs. The pivotal atlas acs 2 timi 51 study proves xarelto 2. An efficacy and safety study for rivaroxaban in patients with acute.
The antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2 timi 51 study randomized 15,526 patients with a recent acs to rivaroxaban 2. In the atlas acs 2timi 51 trial, 2,402 patients 15. Scuoladispecializzazioneinmalaedellapparatocardiovascolare dire8oreprof. Safety and efficacy of rivaroxaban when added to aspirin. The atlas acs 2timi 51 trial and the burden of missing data antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome acs 2thrombolysis in myocardial infarction 51 mori j. Rivaroxaban is the only novel oral anticoagulant oac that has finalised a phase iii clinical trial in acute coronary syndrome acs with a.
A major subanalysis of the atlas acs 2timi 51 study in 7,817 acs patients with a recent stemi demonstrated that xarelto 2. Antixa therapy to lower cardiovascular events in addition to aspirin with or without thienopyridine therapy in subjects with acute coronary syndrome 2 thrombolysis in myocardial infarction 51 trial 2011. The primary efficacy mace end point of cv death, mi and stroke was significantly reduced risk with both doses of rivaroxaban. Approvability of rivaroxaban was considered largely on the basis of the atlas acs 2 timi 51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome acs 2 thrombolysis in myocardial infarction 51 trial, which demonstrated a significant reduction in a composite of cardiovascular death, myocardial infarction, and stroke. An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome. Rivaroxaban and antiplatelet agents in the atlas acs 2 timi 51 trial.
Jul 23, 20 reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in atlas acs 2 timi 51. Fulltext article available only as a pdf file for download. The atlas acs 2timi 51 study multivu, a cision company. Rivaroxaban for pre xaban for preventing adv enting adverse. Rivaroxaban in patients with a recent acute coronary syndrome. Michael gibson, ms, md on behalf of the atlas acs 2 timi. Pr evention of bleeding in patients wi th atrial fibrillation undergoing pci. Subjects are to receive lowdose aspirin therapy 75 to 100 mgday, and enrollment will be stratified based. Lowdose rivaroxaban reduced mortality in patients with a. Pdf acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Cantos results show antiinflammatory therapy lowers.
After stabilisation of the acute coronary syndrome and after. Us fda briefing document albeit in the whole trial population of. Atlas acs 2timi 51 rivaroxaban xarelto stemi study published. Polish registry of acute coronary syndromes pl acs. Atlas acs 2timi 51 a total of 983 primary outcome events would provide a power of 96% to detect a 22. The characteristics and key safety outcomes of included studies are summarized in table 1. Characteristics, treatments and outcomes of patients with acute coronary.
Krantz, md,yz sanjay kaul, mdxk aurora and denver, colorado. Rivaroxabanrivaroxaban in subjects with acute coronary syndrome in subjects with acute coronary syndrome c. Bayer ag announced today that the atlas acs timi 51 trial of rivaroxaban xarelto, bayer and johnson and johnson in patients with acute coronary syndrome acs. Ticagrelor nda 22433 briefing document for cardiovascular and renal. Timi 51 investigated the efficacy and safety of rivaroxaban among men and women, more than 18. Atlas acs 2timi 51 was a phase iii, multicenter, randomized, doubleblind, placebocontrolled clinical trial evaluating an oral, direct factor xa inhibitor rivaroxaban in subjects following an acute coronary syndrome. Events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2 timi 51 study randomized 15,526 patients with a recent acs to rivaroxaban 2. The atlas acs 2timi 51 antixa therapy to lower cardiovascular events in addition to aspirin withwithout thienopyridine therapy in subjects with acute coronary syndrome was a global, double blind, phase iii clinical study involving 15,526 acute coronary syndrome acs. Culpritonly revascularization to treat multivessel disease after primary pci for stemi. Rivaroxaban in patients stabilized after a stsegment. The main study is the atlas acs2timi 51 study the second trial of.
In the atlas acs 2 timi 51 trial, 2,402 patients 15. Acute coronary syndrome acs is a serious and life threatening condition. Atlas acs 2 timi 51 was a phase iii, multicenter, randomized, doubleblind, placebocontrolled clinical trial evaluating an oral, direct factor xa inhibitor rivaroxaban in subjects following an acute coronary syndrome. After an acute coronary syndrome, patients remain at risk for. If the data from atlas acs 2 timi 51 were extrapolated into clinical practice, we could. Rivaroxaban stemi study hits print as fda delivers setback. Timi 51 to evaluate the strategy of combining rivaroxaban with aspirin compared with treatment with aspirin alone in the. Syndrome acs 2thrombolysis in myocardial infarction 51. Dec 17, 2008 gibson cm, chakrabarti ak, mega j, bode c, bassand jp, verheugt fw, bhatt dl, goto s, cohen m, mohanavelu s, burton p, stone g, braunwald e.
Atlas acs 2timi 51 is a phase iii, multicenter, randomized, doubleblind, placebocontrolled clinical trial evaluating an oral, direct factor xa inhibitor rivaroxaban in subjects following an acute coronary syndrome. Applying the spectrum of antithrombotic therapies to your. Methods trial oversight pioneer afpci was an international, multicenter, randomized, openlabel trial. Appraise 2 the second apixaban for prevention of acute ischemic events trial50 atlas acs 2 timi 51 the antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 trial49 atollthe acute stemi treated with primary pci and intravenous. The safety of direct oral anticoagulants with p2y12. Nice issues interim appraisal consultation document acd. Objectivesthe aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among patients with acute coronary syndromes acs in the atlas acs 2 timi 51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 trial. Despite the current standard of prolonged dual antiplatelet therapy with aspirin and a p2y 12 receptor antagonist for patients after an acs, risk for recurrent ischemic cv events remains high. Atlas acs 2 timi 51 assigned 15,526 patients with a recent acs to either twice daily 2. Antixa therapy to lower cardiovascular events in addition to aspirin with or without thienopyridine therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction 46 trial 2009 condition. Comparison of two potent antithrombotic regimens in acs. Prevention of bleeding in patients with atrial fibrillation. Adding rivaroxaban to antiplatelet therapy reduced. Phase iiiphase iii the pivotal atlas acs 2timi 51 study.
The dualpathway strategy after acute coronary syndrome. Bayer has announced that the oral anticoagulant, rivaroxaban, has reduced ischaemic events but increased bleeding in acute coronary syndrome acs patients in the largescale trial atlas acs 2 timi 51. Read the atlas acs 2 timi 51 trial and the burden of missing data, journal of the american college of cardiology on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. The association between baseline wbc count and a composite of thrombolysis in myocardial infarction timi major bleeding or timi minor. All patients were to receive standard medical therapy, including lowdose aspirin. Rivaroxaban reduces events in atlasacs the british. The pivotal atlas acs 2timi 51 study proves xarelto 2. Appraise2the second apixaban for prevention of acute ischemic events trial50 atlas acs 2timi 51the antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 trial49 atollthe acute stemi treated with primary pci and intravenous. The mah must agree the content and format of the prescriber guide together with a.
Patients were enrolled into the trial within 7 days of being admitted to hospital for acute coronary syndrome. Rivaroxaban is not fda approved in the acs setting or in patients with atrial fibrillation undergoing stent placement. Use of direct oral anticoagulants in triple therapy. The atlas acs 2timi 51 trial and the burden of missing. Atlas acs 2timi 51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atoll acute myocardial infarction treated with primary angioplasty and intravenous enoxaparin or unfractionated heparin to lower ischaemic and bleeding events at. The effect of rivaroxaban on myocardial infarction in the atlas acs 2 timi 51 trial article in european heart journal.
For full access to this pdf, sign in to an existing account, or. A subset of patients had their wbc count measured at baseline. Noacs beyond atrial fibrillation february 24 2017 16. Atlas timi 51 jungwon suh seoul national university, korea potent platelet inhibition is a cornerstone in the management of acute coronary syndrome acs. Briefing document for cardiovascular and renal drugs advisory.
Acute cardiovascular care 45 october 2014 with 55 reads. Af and atlas acs 2 timi 51 trials formed the basis of the pioneer afpci trial, which addressed the unmet need of the optimal antithrombotic regimen in patients with both nvaf and coronary artery disease cad. An efficacy and safety study for rivaroxaban in patients. Atlas acs 2timi 51 rivaroxaban xarelto stemi study. One of the authors, sanjay kaul, agreed to answers questions about the topic from cardioexchanges. This study pools data from atlas acs timi 46 acute coronary syndromethrombolysis in myocardial infarction 46 trial and atlas acs 2 timi 51 to evaluate the strategy of combining rivaroxaban with aspirin compared with treatment with aspirin alone in the. The atlas acs 2timi 51 trial and the burden of missing data. The effect of rivaroxaban on myocardial infarction in the atlas acs 2 timi 51 trial. Rivaroxaban meets primary endpoint in atlas acs timi 51. The association between baseline wbc count and a composite of thrombolysis in myocardial infarction timi major. In this doubleblind, placebocontrolled trial, we randomly assigned 15,526 patients with a recent acute coronary syndrome to receive twicedaily doses of either 2. The atlas acs 2 timi 51 trial found rivaroxaban reduced the risk for the composite endpoint of death from cardiovascular causes, mi or stroke vs.
Nov, 2011 results of the highly anticipated atlasacs 2timi 51 demonstrate that acs patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor xa inhibitor rivaroxaban, although at the cost of some additional bleeding complications. Results of the highly anticipated atlas acs 2 timi 51 trial demonstrate that acs patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor xa inhibitor rivaroxaban, although at the cost of some additional bleeding complications. In a recent viewpoint in jacc two members of the fdas cardiovascular and renal drugs advisory committee, mori krantz and sanjay kaul, write about the problem of missing data in the atlas acs 2 timi 51 trial and consider some of the larger implications of missing data in clinical trials. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in atlas acs 2 timi 51. The primary outcome is positive is that good enough. The atlas acs 2timi 51 trial and the burden of missing data core. Ticagrelor has demonstrated survival benefits for patients with acs and has been recommended as a drug of choice in the current practice guidelines. Reduction of stent thrombosis in patients with acute coronary.
1531 483 1087 1581 1522 1234 702 487 583 1028 1308 469 241 549 393 112 123 21 1110 738 748 1597 179 660 1049 1257 1300 1003 652 1578 401 1110 1381 765 1394 1209 373 1123 1408 1000 646 407 214